Volume 16, Issue 3 (May 2014) 16, 331–333; doi: 10.4103/1008-682X.127813
The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions
Evan Y Yu1, William K Oh2
1Department of Medicine, Division of Medical
Oncology, University of Washington, Seattle,
WA 98109, USA; 2Division of Hematology and Medical
Oncology, Tisch Cancer Institute, Icahn School of
Medicine at Mount Sinai, New York, NY 10029, USA.
Correspondence: A/Prof. EY Yu (firstname.lastname@example.org); and Prof. WK Oh (email@example.com)
published online: 08 April 2014
The world of prostate cancer has dramatically changed in the last few
years. The original paradigm that metastatic castration‑resistant prostate cancer (mCRPC) is untreatable is clearly wrong.
Full Text |